NCT04914351View on ClinicalTrials.gov

HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

November 27, 2023

Study Completion Date

December 30, 2023

Conditions
Locally Advanced/Metastatic Solid Tumors
Interventions
DRUG

HY-0102

Multiple dose cohorts, 60 minute IV infusion, every two weeks, 28 days as a cycle

Trial Locations (3)

32827

Sarah Cannon Research Institute, Orlando

75702

Texas Oncology, Tyler

89119

Comprehensive Cancer Centers of Nevada, Las Vegas

All Listed Sponsors
lead

Shanghai HyaMab Biotech Co.,Ltd.

INDUSTRY